Ken Fisher Exelixis, Inc. Transaction History

Fisher Asset Management, LLC

  • $243 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 06, 2024
BUY
$19.25 - $24.13 $14,014 - $17,566
728 Added 232.59%
1,041 $24,000
Q1 2023

May 01, 2023
BUY
$16.3 - $19.41 $5,101 - $6,075
313 New
313 $0
Q1 2018

Apr 19, 2018
BUY
$22.15 - $31.89 $31,297 - $45,060
1,413 Added 16.05%
10,217 $226,000
Q4 2017

Jan 24, 2018
BUY
$24.23 - $30.93 $96 - $123
4 Added 0.05%
8,804 $268,000
Q3 2017

Oct 17, 2017
BUY
$23.35 - $29.24 $205,480 - $257,312
8,800
8,800 $213,000

Others Institutions Holding EXEL

# of Institutions
520
Shares Held
244M
Call Options Held
2.84M
Put Options Held
2.29M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track Ken Fisher's Portfolio

Track Ken Fisher Portfolio

Follow Ken Fisher (Fisher Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email